Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA …
A Wollenberg, A Blauvelt… - British Journal of …, 2021 - academic.oup.com
Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 …
A Wollenberg, A Blauvelt… - BRITISH JOURNAL …, 2021 - publicatt.unicatt.it
Background: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 …
A Wollenberg, A Blauvelt… - The British journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 …
A Wollenberg, A Blauvelt… - The British Journal of …, 2020 - europepmc.org
Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA …
A Wollenberg, A Blauvelt… - British Journal of …, 2021 - Wiley Online Library
Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA …
A Wollenberg, A Blauvelt… - British Journal of …, 2021 - search.ebscohost.com
Background: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
[引用][C] Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials …
A Wollenberg, A Blauvelt, E Guttman‐Yassky… - British Journal of …, 2020 - cir.nii.ac.jp
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized,
double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) …
double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) …
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 …
A Wollenberg, A Blauvelt… - British Journal of …, 2020 - epub.ub.uni-muenchen.de
Background: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA …
A Wollenberg, A Blauvelt… - British Journal of …, 2021 - eprints.whiterose.ac.uk
Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
interleukin‐13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 …
A Wollenberg, A Blauvelt, E Guttman-Yassky, M Worm… - 2021 - scholarworks.iupui.edu
Background: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes
interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …
interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In …